topotecan has been researched along with Acute Disease in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (36.36) | 18.2507 |
| 2000's | 14 (63.64) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Braylan, R; Chen, SF; Fieniewicz, KJ; Gomez, SP; Kahn, S; Leather, H; Lynch, J; Mainwaring, MG; May, WS; Moreb, J; Reddy, V; Rimsza, LM; Rowe, TC; Weeks, FW; Wingard, JR | 1 |
| Abbott, BL; Andreeff, M; Barnes, Y; Colapietro, AM; Marini, F; Sorrentino, BP | 1 |
| Alvarez, R; Beran, M; Cortes, J; Estey, E; Giles, FJ; Kantarjian, H; Thomas, D; Tsimberidou, AM | 1 |
| Gore, SD; Malek, SN | 1 |
| Berger, SJ; Cooper, BW; Donaher, E; Gerson, SL; Gosky, DM; Green, SB; Hoppel, CL; Ingalls, ST; Lazarus, HM; Li, X; Rosenthal, NS | 1 |
| Estey, EH; Thall, PF | 1 |
| Kolb, EA; Steinherz, PG | 1 |
| Diehl, V; Hoffmann, M; Seiberlich, B; Staib, P; Tesch, H; Weihrauch, MR | 1 |
| Adjei, AA; Ames, MM; Atherton, P; Erlichman, C; Gojo, I; Greer, J; Karp, JE; Kaufmann, SH; Kottke, TJ; Letendre, L; Litzow, MR; Loegering, DA; Reid, JM; Safgren, S; Sloan, JA; Svingen, PA | 1 |
| Albitar, M; Day, A; Do, KA; Estey, E; Giles, FJ; Jilani, I; Johnson, M; Kantarjian, H; Keating, M; O'brien, S; Pierce, S; Verstovsek, S | 1 |
| Adjei, A; Burke, PJ; Cheng, YC; Donehower, RC; Gore, SD; Grochow, LB; Jones, RJ; Kaufmann, SH; Rowinsky, EK | 1 |
| Beran, M; Cazenave, L; Ellis, A; Kantarjian, HM; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W; Rios, MB; Zwelling, L | 1 |
| Crumpacker, CS; Dezube, BJ; Li, CJ; Pardee, AB; Zhang, LJ | 1 |
| Baker, SD; Evans, WE; Furman, WL; Pratt, CB; Rivera, GK; Stewart, CF | 1 |
| Baker, SD; Bowling, MK; Chen, TL; Donehower, RC; Gore, SD; Kaufmann, SH; Miller, CB; Rowinsky, EK; Sartorius, SE | 1 |
| Beare, S; Crump, M; Eisenhauer, E; Hedley, D; Lipton, J; Minden, M; Shepherd, F; Stewart, K; Sutton, D | 1 |
| Kantarjian, H | 1 |
| Beran, M; Cortes, J; Estey, E; Giles, F; Kantarjian, H; Keating, M; Koller, C; O'Brien, S | 1 |
| Ciolli, S; Fanci, R; Leoni, F; Nozzoli, C; Rossi Ferrini , P; Santini, V | 1 |
| Kancherla, R; Nair, JS; Seiter, K; Traganos, F; Tse-Dinh, YC | 1 |
| Chiusolo, P; Leone, G; Mazzotta, S; Mele, L; Pagano, L; Putzulu, R; Voso, MT | 1 |
| Donehower, RC; Grochow, LB; Hendricks, CB; Kaufmann, SH; Rowinsky, EK | 1 |
1 review(s) available for topotecan and Acute Disease
| Article | Year |
|---|---|
New developments in the treatment of acute myeloid leukemia: focus on topotecan.
Topics: Acute Disease; Antineoplastic Agents; Combined Modality Therapy; Humans; Leukemia, Myeloid; Prognosis; Topoisomerase I Inhibitors; Topotecan | 1999 |
13 trial(s) available for topotecan and Acute Disease
| Article | Year |
|---|---|
Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; DNA Fragmentation; DNA Topoisomerases, Type II; Enzyme Induction; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Topotecan | 2002 |
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
Topics: Acute Disease; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Humans; Infusions, Intravenous; Leukemia, Myeloid; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Survival Rate; Topotecan; Treatment Outcome | 2002 |
A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Chemical and Drug Induced Liver Injury; DNA Topoisomerases, Type II; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Induction; Enzyme Inhibitors; Etoposide; Female; Gastrointestinal Diseases; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Topoisomerase I Inhibitors; Topotecan | 2003 |
A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Dexamethasone; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukemia; Male; Recurrence; Thiotepa; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cytarabine; Disease-Free Survival; Female; Hemoglobinometry; Humans; Leukemia, Myeloid; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Topotecan; Treatment Outcome | 2004 |
Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Carboplatin; Cell Cycle Proteins; Combined Modality Therapy; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; HL-60 Cells; Humans; Immunoblotting; Infusions, Intravenous; Leukemia; Male; Middle Aged; Neoplasm Recurrence, Local; Proliferating Cell Nuclear Antigen; Topotecan; Treatment Outcome | 2005 |
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Camptothecin; Daunorubicin; Drug Administration Schedule; Drug Resistance, Multiple; Female; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia; Male; Middle Aged; Mouth Mucosa; Quinidine; Remission Induction; Stomatitis; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1994 |
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Camptothecin; DNA; DNA Topoisomerases, Type I; Drug Administration Schedule; Female; Humans; Irinotecan; Leukemia; Male; Middle Aged; Topoisomerase I Inhibitors; Topotecan | 1993 |
Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Infant; Infusions, Intravenous; Leukemia; Male; Metabolic Clearance Rate; Recurrence; Topotecan | 1996 |
A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Bone Marrow; DNA Topoisomerases, Type I; Female; Humans; Leukemia; Male; Middle Aged; Mucous Membrane; Neoplasm Recurrence, Local; Topotecan; Treatment Outcome | 1996 |
Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cohort Studies; DNA Topoisomerases, Type II; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Topotecan | 1999 |
Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Humans; Leukemia; Middle Aged; Recurrence; Topotecan; Treatment Outcome | 2000 |
The association of topotecan and cytarabine in the treatment of secondary or relapsed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Second Primary; Recurrence; Therapeutic Equivalency; Topotecan; Treatment Outcome | 2001 |
8 other study(ies) available for topotecan and Acute Disease
| Article | Year |
|---|---|
Low levels of ABCG2 expression in adult AML blast samples.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood Cells; Bone Marrow Cells; Drug Resistance, Neoplasm; Female; Fetal Blood; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Idarubicin; Infant, Newborn; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplastic Stem Cells; RNA, Messenger; RNA, Neoplasm; Topotecan | 2002 |
Commentary: topoisomerases as targets in acute leukemia: I, II, I plus II or none?
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Leukemia; Neoplasm Proteins; Remission Induction; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome | 2003 |
New designs for phase 2 clinical trials.
Topics: Acute Disease; Adenine Nucleotides; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bayes Theorem; Bias; Biomarkers; Clinical Trials, Phase II as Topic; Clofarabine; Confounding Factors, Epidemiologic; Cytarabine; Daunorubicin; Drug Carriers; False Negative Reactions; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid; Liposomes; Middle Aged; Patient Selection; Randomized Controlled Trials as Topic; Remission Induction; Research Design; Thalidomide; Topotecan; Treatment Outcome | 2003 |
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Cytarabine; Disease Progression; Female; HLA Antigens; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Predictive Value of Tests; Proportional Hazards Models; Remission Induction; Solubility; Topotecan; Treatment Outcome; Vidarabine | 2007 |
Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication.
Topics: Acute Disease; Antiviral Agents; Camptothecin; Cells, Cultured; Chronic Disease; Curcumin; Gene Expression Regulation, Viral; HIV Infections; HIV Long Terminal Repeat; HIV-1; In Vitro Techniques; Naphthoquinones; RNA, Viral; Topotecan; Virus Replication | 1993 |
Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Evaluation; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Topotecan; Vidarabine | 2001 |
Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia. Correlation of clinical and cell culture studies.
Topics: Acute Disease; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Cytarabine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Isoenzymes; Leukemia; Leukocytes; Lymphoma, Non-Hodgkin; Mitoxantrone; Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2000 |
Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
Topics: Acute Disease; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Camptothecin; CHO Cells; Cricetinae; DNA Topoisomerases, Type I; DNA, Neoplasm; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Flow Cytometry; Leukemia; Membrane Glycoproteins; Quinidine; Topotecan; Tumor Cells, Cultured | 1992 |